Lallemand Health Solutions will showcase its latest clinically documented microbiome solutions at Vitafoods Bangkok 2026, taking place September 2-4, helping brands address some of the fastest-growing health opportunities across the Asia-Pacific region.
As consumers across APAC increasingly seek proactive approaches to aging well, maintaining cognitive performance, supporting digestive health, and improving overall wellbeing, Lallemand Health Solutions continues to invest in science-backed biotic innovations designed to deliver meaningful health benefits and strong market differentiation.
“Asia-Pacific remains one of the most dynamic and innovative health ingredients markets in the world,” says Romane Maillet, Product Category Manager. “At Vitafoods Bangkok, we look forward to sharing new clinical findings and helping our partners develop next-generation microbiome solutions that respond to evolving consumer expectations.”
Healthy Aging: Supporting Mobility, Vitality and Quality of Life
Healthy aging continues to gain momentum throughout Asia, driven by rapidly aging populations and growing consumer interest in maintaining independence, mobility, and overall vitality. At Vitafoods Bangkok, Lallemand Health Solutions will spotlight Cerenity™, a clinically documented probiotic solution designed to support healthy aging through the gut-muscle axis. Recent clinical research demonstrated beneficial effects on physical performance and quality of life in older adults, highlighting the potential of targeted microbiome interventions to support aging populations. The company’s healthy aging platform also includes innovative solutions addressing cardiovascular and cognitive health, helping brands build comprehensive wellness offerings for aging consumers.
New Insights into Cognitive Performance
Demand for solutions supporting focus, mental performance, and cognitive resilience continues to grow across Asia-Pacific, particularly among students, professionals, gamers, and active older adults. Lallemand Health Solutions will present new data supporting its expanding cognitive health portfolio, including results from a recent clinical study evaluating Cerebiome® in action video gamers. Preliminary findings[1] demonstrated measurable improvements in several attention-related parameters, including:
- Reaction time
- Processing speed
These results further reinforce the growing evidence supporting the gut-brain axis and open new opportunities for brands targeting cognitive capacities and mental performance.
Clinically Documented Solutions for Women’s Health
Lallemand Health Solutions will also present its portfolio of targeted probiotic solutions supporting women’s health across key life stages, featuring innovations such as:
- Prenatis™, evaluated in a clinical study involving 180 pregnant women, demonstrating benefits for maternal health and early infant microbiome development.
- Lacidofil®, shown to support microbiota balance around C-section delivery.
- L. plantarum Rosella®[2], supported by six clinical studies involving more than 800 women, for vaginal microbiota balance.
- B. bifidum Rosell®-71, clinically evaluated for digestive comfort during menstruation.
Together, these solutions provide healthcare-focused brands with scientifically substantiated approaches to female health and wellbeing through microbiome modulation.
Experience Innovation at Booth #H7-P41
Visitors to booth #H7-P41 will have the opportunity to meet Lallemand Health Solutions experts, explore recent clinical developments, discuss product innovation opportunities, and discover FizzBiotics™ by Lallemand, an engaging sparkling probiotic concept designed to elevate consumer experience and support product differentiation.
Whether developing solutions for healthy aging, cognitive capacities, digestive wellness, or women’s health, brands can leverage Lallemand Health Solutions’ extensive scientific, regulatory, and manufacturing expertise to accelerate innovation and bring differentiated products to market.
[1] These results should not be considered definitive, as the manuscript is currently under peer review and may be revised.
[2] L. plantarum ROSELLA is L. plantarum P17630 (Proge P17630®), licensed from PROGE FARM®, Italy.
